Every S-1 that GeoVax Labs, Inc. New (GOVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow GOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVX filings page.
GeoVax Labs, Inc. (GOVX) filed a resale registration for up to 11,395,256 shares of common stock issuable upon exercise of an August 2026 common warrant held by a single institutional selling stockholder. The company will not receive proceeds from resales, only from any cash warrant exercises.
GeoVax is a clinical-stage biotech focused on its GEO-MVA mpox/smallpox vaccine, with a pivotal Phase 3 trial planned for the fourth quarter of 2026, and Gedeptin®, an oncolytic gene-directed therapy for head and neck cancer with a Phase 2 trial planned for the second half of 2027. The company incurred a $21.5 million net loss in 2025 and $9.7 million for the six months ended June 30, 2026, has a going concern opinion, and believes existing cash funds operations only into October 2026, while also facing Nasdaq listing deficiency notices and an upcoming delisting hearing.
GeoVax Labs, Inc. is registering 7,639,967 shares of common stock for resale by existing investors. These shares are issuable upon exercise of May 2026 inducement and PIPE-related warrants, and the company will not receive any proceeds from resale transactions.
GeoVax may receive cash only if holders exercise the May 2026 warrants, which could generate up to approximately $8.6 million in gross proceeds. Recent financing included a May 2026 warrant exercise inducement yielding about $844,080 in net proceeds and a May 2026 private placement with roughly $2.7 million in net proceeds.
The company is a clinical-stage biotech focused on GEO‑MVA, a Modified Vaccinia Ankara vaccine candidate for mpox and smallpox, with a pivotal Phase 3 trial planned for the second half of 2026, and Gedeptin, an oncolytic gene-directed therapy moving toward Phase 2 in head and neck cancer. GeoVax has no product revenue, reported net losses of approximately $21.5 million in 2025 and $5.3 million for the three months ended March 31, 2026, and has received a going concern opinion, noting existing cash is expected to fund operations only into June 2026.
GeoVax Labs, Inc. filed a resale registration covering up to 865,804 shares of common stock issuable from February 2026 common stock purchase warrants held by institutional investors. The company will not receive proceeds from share resales, only from any cash exercises of these warrants.
GeoVax is a clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and cancers, with lead programs in mpox/smallpox (GEO‑MVA), head and neck cancer (Gedeptin) and a next-generation COVID‑19 vaccine (GEO‑CM04S1). The prospectus highlights substantial ongoing losses, a recent net loss of about $21.5 million, a going concern warning, limited cash expected to fund operations into mid‑second quarter 2026, and significant Nasdaq listing and dilution risks.
GeoVax Labs, Inc. is registering 1,269,316 shares of common stock for resale by institutional investors holding March 2026 Common Warrants. These shares will be issued if the warrants are exercised. GeoVax will not receive proceeds from resale transactions, only from any cash exercises of the warrants.
The company is a clinical-stage biotech focused on vaccines and immunotherapies, including programs for mpox/smallpox, head and neck cancers, and COVID-19. GeoVax reports a history of losses, a 2025 net loss of about $21.5 million, going-concern uncertainty, and a need for additional funding beyond mid–second quarter 2026.
GeoVax Labs, Inc. is offering 18,292,683 Common Units and 18,292,683 Pre-Funded Units, plus up to 36,585,366 shares of common stock underlying warrants, in a best efforts public sale. Each Common Unit includes one share of common stock and two five-year Common Warrants exercisable at $0.41 per share, while each Pre-Funded Unit substitutes a pre-funded warrant exercisable at $0.00001 plus two Common Warrants. The assumed public price is $0.41 per Common Unit and $0.40999 per Pre-Funded Unit, and GeoVax expects net proceeds of about $6,8 million, primarily to fund research, clinical trials, manufacturing, and working capital.
Before this deal, GeoVax had 30,058,786 shares outstanding as of December 12, 2025; this would rise to 48,351,469 shares if all Common Units are sold and no warrants are exercised. The company is a clinical-stage biotech with programs including Phase 2 trials for its COVID-19 vaccine candidate GEO-CM04S1, a planned Phase 2 study of its oncolytic therapy Gedeptin for head and neck cancer, and a GEO-MVA Mpox/smallpox vaccine expected to move directly into Phase 3 in 2026.
GeoVax reports it has never generated product revenue, incurred a net loss of approximately $17.0 million for the nine months ended September 30, 2025 and $25 million for 2024, and has received a going concern opinion from its auditors. Management warns the business requires continued external funding, highlights substantial outstanding and reserved equity (including 40,027,849 warrant shares and 2,033,648 shares reserved under stock plans), and notes significant risks around regulation, competition, intellectual property, Nasdaq listing, and potential dilution from additional equity issuance.